Jun 9, 2022
UCB is ready to present bimekizumab’s results from BE MOBILE 1 for non-radiographic axial spondyloarthritis (nr-axSpA), BE MOBILE 2 for ankylosing spondylitis (AS), and BE COMPELTE study for psoriatic arthritis (PsA).
seen from United States
seen from Türkiye
seen from United States
seen from China
seen from United States
seen from United States
seen from United States
seen from Japan
seen from Saudi Arabia
seen from Poland
seen from Russia
seen from United States
seen from China
seen from United Kingdom
seen from United States
seen from Philippines
seen from United States
seen from China
seen from United States
seen from United States
UCB is ready to present bimekizumab’s results from BE MOBILE 1 for non-radiographic axial spondyloarthritis (nr-axSpA), BE MOBILE 2 for ankylosing spondylitis (AS), and BE COMPELTE study for psoriatic arthritis (PsA).